TABLE 1.
Patient demography and disease characteristics
| Characteristic | Placebo group | 1% cidofovir group | 3% cidofovir group | 5% cidofovir group | All patients |
|---|---|---|---|---|---|
| Total no. of patients | 32 | 20 | 21 | 23 | 96 |
| Gender (no. [%]) | |||||
| Female | 14 (44) | 11 (55) | 11 (52) | 13 (57) | 49 (51) |
| Male | 18 (56) | 9 (45) | 10 (48) | 10 (43) | 47 (49) |
| Age (yr)a | 33 (23–51) | 37 (22–58) | 33 (21–52) | 37 (23–66) | 35 (21–66) |
| Duration of herpes (yr)a | 3 (0–19) | 7 (0–34) | 6 (0–20) | 4 (0–20) | 4 (0–34) |
| No. of recurrences in past 6 moa | 3 (0–12) | 3 (0–12) | 4 (0–20) | 3 (0–12) | 3 (0–20) |
| No. of lesions at entry (range) | 1–2 | 1–2 | 1–3 | 1–2 | 1–3 |
| Lesion stage at entry (no. [%] of patients) | |||||
| Papule or edema | 28 (88) | 19 (95) | 19 (90) | 18 (78) | 84 (88) |
| Vesicle or pustule | 24 (75) | 13 (65) | 15 (71) | 14 (61) | 66 (69) |
| Ulcer | 12 (38) | 9 (45) | 4 (19) | 10 (43) | 35 (36) |
| Time (h) from lesion onset to drug application (range) | 8 (2–13) | 5 (2–12) | 8 (2–12) | 6 (1–13) | 7 (1–13) |
a
Median.